Podcast peptide claims, fact-checked

How we checked

Peptide claims travel through clips, summaries and reposts, and each step loses detail. So we started from the source: the full transcript that Huberman Lab publishes with its episode "Peptides: The Science, Uses & Safety", in which Andrew Huberman interviews Dr. Abud Bakri, an internal medicine physician ¹. Every claim below is attributed to the person the transcript shows saying it.

Each claim gets one of four verdicts: accurate; accurate, with a caveat; inaccurate; or can't be checked, when no source exists that could settle it. Every source was read on October 2, 2026. We quote the episode once, where the exact words matter, and describe the other claims in our own words.

What the episode said about FDA

1. BPC-157 was never approved by FDA

Accurate. Bakri said BPC-157 never received FDA approval ¹. FDA has never approved a drug containing it; the agency's own list of bulk substances that may present significant safety risks includes it ². Our encyclopedia grades its evidence Low; the BPC-157 entry has the details.

2. It was moved into Category 2 in late 2024

Inaccurate on the date. In Bakri's words: "In late 2024, BPC 157 and 20 other peptides got moved" ¹. He repeated the year later in the episode. FDA's page of substances that may present significant safety risks gives the date BPC-157 was added to Category 2 as September 29, 2023, and lists the agency's concerns: possible immune reactions for some routes of administration, and difficulties with peptide-related impurities and with characterising the active ingredient ². We did not check the count of other peptides.

3. It came off Category 2 in April but is not in Category 1

Accurate, both when the episode aired and on October 2, 2026. Bakri said BPC-157 had been removed from Category 2 that April without being placed in Category 1, the list that would let pharmacies compound it under FDA's interim policy ¹. FDA announced the removal on April 15, 2026 ³. Its category list, last updated May 14, 2026, names BPC-157 in none of its three categories ⁴, and as of October 2, 2026 no Federal Register document has added it to the 503A list ⁵.

4. The first review round would cover seven peptides

Accurate. Bakri predicted that FDA's first round of reconsideration would take up seven peptides, BPC-157 and TB-500 among them ¹. On July 23 and 24, FDA's compounding advisory committee reviewed seven and recommended six for the 503A list, BPC-157 by 8 votes to 6 ⁶. A recommendation is advice, not a rule: as of October 2, 2026, FDA has not acted on it ⁴⁵.

What the episode said about sport

5. BPC-157 is on WADA's list

Accurate. Bakri said BPC-157 is on the World Anti-Doping Agency's list ¹. WADA's 2026 Prohibited List names it among the non-approved substances in class S0, which are prohibited at all times, and the 2027 list keeps the same wording ⁷. For athletes, that settles it whatever happens at FDA.

The claim about pentadeca arginate

6. Pharmacies relabel BPC-157 as pentadeca arginate

Can't be checked. Bakri said compounding pharmacies sell BPC-157 under the name PDA, or pentadeca arginate ¹. We looked for anything that could confirm or refute what that product is. As of October 2, 2026, PubMed holds no paper naming pentadeca arginate and PubChem has no compound record under that name ⁸. Whether a product sold as pentadeca arginate contains BPC-157, a salt of it or something else could only be settled by testing samples, and we found no published test.

What the episode said about the evidence

7. There is far more animal data than human data

Accurate. Huberman made this point while discussing whether BPC-157 would help an injured dog ¹. The most thorough summary we found is a 2025 systematic review in the HSS Journal: from 544 records it included 36 studies, of which 35 were preclinical and 1 was clinical, and it found no clinical safety data ⁹.

That one clinical study was a telephone survey of patients at a single hormone clinic in Florida, looking back at knee injections given in 2019 and 2020. Of 16 patients reached, 14 reported relief, by the authors' own count; there was no control group and no validated measure of pain or function ¹⁰. Since the review, a pilot study gave two adults intravenous infusions of 10 mg and then 20 mg and reported no changes in heart, liver, kidney, thyroid or glucose markers; both had used the peptide before, and there was no comparison group ¹¹. No controlled human trial of BPC-157 has been published.

8. Animal studies show no cancer signal

Accurate, with a caveat. Bakri said the animal literature shows no signal for cancer, and added that most of it comes from one research group, so it should be read carefully ¹. The systematic review agrees on the first part: preclinical safety studies reported no adverse effects across several organ systems ⁹. The caveat is what those studies can show. Short animal studies are not built to detect cancer risk in people, and with no clinical safety data at all ⁹, the absence of a signal is not evidence of long-term safety. FDA's stated concerns are different again: immune reactions and product quality ².

What we didn't check

BPC-157 also came up on a September 2026 episode of The Joe Rogan Experience with Huberman as a guest. The summaries of that conversation published online disagree with each other about what was described, and we found no transcript we could verify. So this article quotes none of them. When a claim reaches you through a clip or a summary, finding the full episode and the timestamp is the first check, and often the one that changes the story.

How to check a podcast claim yourself

Four checks catch most problems. First, go to the transcript or the full episode, not the clip. Second, check dates and statuses against the regulator's own record: FDA's page of substances with significant safety risks lists the date each one was added ², and WADA publishes its list every year ⁷. Third, ask whether a study was in animals or people, how many people, and whether there was a control group. Fourth, ask whether the claim is still true: the legal status of BPC-157 has changed twice since 2023, and a correct statement in June can be out of date by October.

Our BPC-157 and TB-500 Low entries keep the evidence and status for both peptides current, and our report on the July votes explains what the committee's recommendations do and don't change.

Frequently asked questions

What did the Huberman Lab peptides episode get right about BPC-157?

Of eight claims we checked, six hold up: it was never FDA-approved, it left Category 2 in April 2026 without entering Category 1, the first review round covered seven peptides, it is on WADA's list, animal data far outweigh human data, and animal studies show no cancer signal, with caveats.

When was BPC-157 put in FDA's Category 2?

On September 29, 2023, according to FDA's own page of substances that may present significant safety risks. The episode said late 2024.

Is BPC-157 legal to compound now?

Not on the record as of October 2, 2026. FDA took it out of Category 2 in April 2026 but did not place it in Category 1, and although an advisory committee recommended it for the 503A list in July, no document has added it.

Are there human studies of BPC-157?

Very few. A 2025 systematic review found one clinical study among 36, a retrospective survey of 16 knee-injection patients; a two-person intravenous safety pilot followed. No controlled human trial has been published.

Is BPC-157 banned in sport?

Yes. WADA's 2026 Prohibited List names it among the non-approved substances in class S0, prohibited at all times, and the 2027 list keeps it.

Related on Grey Peptides

• What the July 2026 PCAC votes did and didn't change
• FDA's Category 1 and 2 explained
• What peptide therapy really costs in 2026

Sources

1. Huberman Lab. Peptides: The Science, Uses & Safety, with Dr. Abud Bakri. Episode page and transcript, hubermanlab.com, published June 1, 2026; read October 2, 2026.
2. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (fda.gov); BPC-157 row: 503A, date added to category 2 September 29, 2023; read October 2, 2026.
3. Grey Peptides. FDA removes twelve peptides from Category 2 (/news/fda-12-peptides-category-2-removal/), April 22, 2026, from FDA's April 15, 2026 announcement.
4. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), updated May 14, 2026; read October 2, 2026.
5. Federal Register API: search for documents on 503A bulk drug substances published since September 20, 2026, none found; queried October 2, 2026.
6. Grey Peptides. The July 2026 PCAC votes (/news/pcac-july-2026-votes/), September 25, 2026, from FDA's meeting materials.
7. World Anti-Doping Agency. The 2026 Prohibited List and the 2027 Prohibited List, class S0 (non-approved substances), which names BPC-157 among its examples. Read October 2, 2026.
8. Grey Peptides Registry (assets/registry.json): searches of PubMed and PubChem for pentadeca arginate, October 2, 2026, with no record found in either.
9. Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 21(4), 485-495. PMID: 40756949
10. Lee, E., & Padgett, B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 27(4), 8-13. PMID: 34324435
11. Lee, E., & Burgess, K. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 31(5), 20-24. PMID: 40131143

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.